IPSS trends for Cs-131 permanent prostate brachytherapy

      Purpose: Cs-131 has an implied advantage of shortening the duration of side-effects due to its shorter half-life (9.7 days) versus I-125 (59.4 days). Over 90 patients have had permanent prostate implant brachytherapy with Cs-131 seeds at Geisinger Medical Center since March 2006. Patients are routinely followed with serial IPSS to assess the extent of their urinary symptoms.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect